levodopa has been researched along with enkephalin, leucine in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (10.47) | 18.7374 |
| 1990's | 12 (13.95) | 18.2507 |
| 2000's | 48 (55.81) | 29.6817 |
| 2010's | 15 (17.44) | 24.3611 |
| 2020's | 2 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Schreiber, V | 1 |
| Borison, RL; Diamond, BI | 1 |
| De Ceballos, ML; Jenner, P; Marsden, CD; Rose, S; Taylor, MD | 1 |
| Holman, RB; Widdowson, PS | 1 |
| Chase, TN; Engber, TM; Gerfen, CR; Kuo, S; Susel, Z | 1 |
| Liu, DK | 1 |
| Pan, JB | 1 |
| Chen, SD; Pan, GB; Xu, DL; Yu, WC | 1 |
| Jenner, P; Marsden, CD | 1 |
| Boyce, S; De Ceballos, ML; Jenner, P; Marsden, CD | 1 |
| Koskinen, V; Laakso, K; Lönnberg, P; Rinne, JK; Rinne, JO; Rinne, UK; Tenovuo, O | 1 |
| Rinne, UK | 1 |
| Daniel, SE; Eve, DJ; Foster, OJ; Kingsbury, A; Lees, AJ; Marsden, CD; Nisbet, AP | 1 |
| Jenner, P; Jolkkonen, J; Marsden, CD | 1 |
| Jenner, P; Jolkkonen, J; Marsden, CD; Zeng, BY | 1 |
| Agid, Y; Augood, SJ; Emson, PC; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Luquin, MR; Obeso, JA | 1 |
| Dziewczapolski, G; Gershanik, OS; Nieoullon, A; Raisman-Vozari, R; Salin, P | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Morissette, M; Soghomonian, JJ | 1 |
| Björklund, A; Cenci, MA; Lee, CS | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A | 1 |
| Damier, P; Féger, J; Hirsch, EC; Tremblay, L | 1 |
| Jenner, P; MacKenzie, GM; Pearce, RK; Zeng, BY | 1 |
| Bordet, R; Ridray, S; Schwartz, JC; Sokoloff, P | 1 |
| Andren, PE; Gunne, L; Svenningsson, P | 1 |
| Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC | 1 |
| Andersson, KE; Andersson, M; Cenci, MA; Johansson, PA | 1 |
| Andrén, PE; Gunne, L; Hurd, YL; Pirker, W; Pontén, H; Tedroff, J | 1 |
| Carta, A; Fenu, S; Morelli, M | 1 |
| Schomburg, ED; Steffens, H; Wada, N | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
| Kerkerian-Le Goff, L; Liévens, JC; Nieoullon, A; Salin, P | 1 |
| Andersson, M; Cenci, MA; Konradi, C | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
| Bédard, PJ; Birdi, S; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH | 1 |
| Carta, AR; Cauli, O; Morelli, M; Pinna, A | 1 |
| Di Monte, DA; Langston, JW; Police, S; Quik, M | 1 |
| Björklund, A; Cenci, MA; Kirik, D; Winkler, C | 1 |
| Calon, F; Di Paolo, T | 1 |
| Cenci, MA | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY | 1 |
| Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E | 1 |
| Andersson, M; Cenci, MA; Westin, JE | 1 |
| Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Jaber, M; Ravenscroft, P | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Bonastre, M; Hirsch, EC; Jimenez, A; Marin, C; Périer, C; Tolosa, E | 1 |
| Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 2 |
| Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 1 |
| Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Bourhis, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Crossman, AR; Dovero, S; Gross, CE; Guigoni, C; Li, Q | 1 |
| Dagostino, P; Katz, J; Soghomonian, JJ; Wang, H | 1 |
| Cao, X; Chen, Z; Guan, Q; Sun, S; Wang, L; Xu, Y | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L | 1 |
| Cenci, MA; Konradi, C; Strome, EM; Vercammen, L; Westin, JE | 1 |
| Guan, Q; He, Y; Tan, L; Zhan, Q | 1 |
| Cheetham, S; Jenner, P; Lane, EL | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Danysz, W; Dekundy, A; Quack, G; Valastro, B | 1 |
| Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ | 1 |
| Caron, MG; Gainetdinov, RR; Hallett, PJ; Isacson, O; Patterson, M; Reske-Nielsen, C; Sotnikova, TD; Vinuela, A | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A; Mammo, SE | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A | 1 |
| Andrén, PE; Bezard, E; Bourdenx, M; Crossman, AR; Fälth, M; Li, Q; Nilsson, A; Wadensten, H | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 1 |
| Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC | 1 |
| Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Schäfer, MK; Weihe, E | 1 |
| Ahn, S; Hong, S; Jang, J; Jeon, S; Jung, YR; Kim, J; Oh, JY; Park, HJ; Park, SU; Shin, HS; Song, MA; Song, TJ | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Altwal, F; Beverley, JA; F Voelkner, NM; Padovan-Neto, FE; Patterson, S; Steiner, H; West, AR | 1 |
| Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X | 1 |
3 review(s) available for levodopa and enkephalin, leucine
| Article | Year |
|---|---|
Chronic pharmacological manipulation of dopamine receptors in brain.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Bromocriptine; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Pergolide; Receptors, Dopamine; Trifluoperazine | 1987 |
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Topics: Animals; Antiparkinson Agents; Biological Transport, Active; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Haplorhini; Humans; Levodopa; Neural Pathways; Neuronal Plasticity; Neurons, Efferent; Parkinson Disease; Receptors, Dopamine D2; Substance P; Time Factors | 2000 |
Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Enkephalins; Humans; Levodopa; Protein Precursors; Receptors, GABA | 2002 |
83 other study(ies) available for levodopa and enkephalin, leucine
| Article | Year |
|---|---|
[Dopaminergic neurons in the hypothalamo-hypophyseal system (IV): endocrinologic aspects of endogenous euphorigens].
Topics: Analgesics, Opioid; Antipsychotic Agents; Apomorphine; Dopamine; Endorphins; Enkephalins; Ergolines; Hallucinogens; Humans; Hypothalamo-Hypophyseal System; Levodopa; Neurons; Pituitary Hormones, Anterior; Serotonin | 1977 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Topics: Animals; Carbidopa; Cholecystokinin; Chromatography, High Pressure Liquid; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neuropeptides; Neurotensin; Oxidopamine; Prosencephalon; Rats; Rats, Wistar; Substance P; Substantia Nigra | 1992 |
Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates.
Topics: Animals; beta-Endorphin; Dopamine; Endorphins; Enkephalin, Leucine; Ethanol; Levodopa; Male; Naloxone; Narcotic Antagonists; Potassium; Rats; Rats, Inbred Strains | 1992 |
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Drug Administration Schedule; Dynorphins; Enkephalins; Functional Laterality; Globus Pallidus; Glutamate Decarboxylase; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1991 |
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Enkephalin, Leucine; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
[Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
Topics: Animals; Caudate Nucleus; Drug Synergism; Enkephalins; Levodopa; MSH Release-Inhibiting Hormone; Parkinson Disease; Rats | 1985 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; Levodopa; Male; Middle Aged; MSH Release-Inhibiting Hormone; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Stereotyped Behavior | 1987 |
Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
Topics: Animals; Basal Ganglia; Bromocriptine; Carbidopa; Dopamine; Dopamine Antagonists; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neurotensin; Pergolide; Rats; Rats, Inbred Strains; Trifluoperazine | 1986 |
Brain enkephalin receptors in Parkinson's disease.
Topics: Aged; Brain; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Female; Humans; Kinetics; Levodopa; Male; Naloxone; Nucleus Accumbens; Parkinson Disease; Receptors, Dopamine; Receptors, Opioid; Substantia Nigra | 1983 |
Recent advances in the treatment of Parkinson's disease.
Topics: Brain; Bromocriptine; Drug Therapy, Combination; Endorphins; Enkephalins; Humans; Levodopa; Mental Disorders; Parkinson Disease; Receptors, Dopamine | 1980 |
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Autoradiography; Basal Ganglia; Dopamine Agents; Enkephalins; Female; Gene Expression; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Protein Precursors; RNA, Messenger; Sensitivity and Specificity; Tachykinins | 1995 |
L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Callithrix; Caudate Nucleus; Enkephalins; Female; Gene Expression; In Situ Hybridization; Levodopa; Male; Mazindol; Motor Activity; Nucleus Accumbens; Putamen; RNA, Messenger; Substance P | 1995 |
Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.
Topics: Animals; Base Sequence; Behavior, Animal; Carbidopa; Enkephalins; Female; Gene Expression Regulation, Enzymologic; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Molecular Sequence Data; Neostriatum; Oligonucleotide Probes; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Tachykinins | 1995 |
Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum.
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine Agents; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Macaca fascicularis; MPTP Poisoning; Neostriatum; Oligonucleotides, Antisense; Parkinson Disease, Secondary; Protein Precursors; Putamen; RNA, Messenger; Tachykinins | 1995 |
Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat.
Topics: Animals; Corpus Striatum; Enkephalins; Female; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; Tachykinins; Time Factors | 1997 |
Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Caudate Nucleus; Dopamine Agonists; Enkephalins; Female; Imidazoles; In Situ Hybridization; Levodopa; Macaca fascicularis; Ovariectomy; Parkinson Disease, Secondary; Protein Precursors; Putamen; Receptors, Dopamine D2; RNA, Messenger; Transcription, Genetic | 1997 |
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
Topics: Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Oxidopamine; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Tachykinins | 1998 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area | 1999 |
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
Topics: Animals; Autoradiography; Brain; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; Nitriles; Oligonucleotide Probes; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2000 |
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Dizocilpine Maleate; Dopamine Agonists; Dopamine Antagonists; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression; Levodopa; Male; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Sympatholytics; Tachykinins; Tetrahydronaphthalenes; Tritium; Ventral Tegmental Area | 2000 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Enkephalins; Gene Expression; Genes, Immediate-Early; Levodopa; Nerve Degeneration; Oxidopamine; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Raclopride; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Substance P; Substantia Nigra; Sympatholytics; Tritium | 2000 |
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Locomotion; Male; Mazindol; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Protein Precursors; Recovery of Function; RNA, Messenger; Substantia Nigra; Tachykinins; Tritium; Tyrosine 3-Monooxygenase | 2001 |
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Basal Ganglia; Behavior, Animal; Binding Sites; Cerebral Cortex; Diprenorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Narcotic Antagonists; Oxidopamine; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Sympatholytics; Tritium | 2001 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enkephalins; Female; In Situ Hybridization; Injections, Subcutaneous; Levodopa; Ligands; Male; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Protein Precursors; Putamen; RNA, Messenger; Tritium | 2001 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulation; Drug Interactions; Drug Tolerance; Dynorphins; Enkephalins; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; RNA, Messenger; Sympatholytics; Up-Regulation | 2001 |
Parallel nociceptive reflex pathways with negative and positive feedback functions to foot extensors in the cat.
Topics: Analgesics; Analgesics, Opioid; Animals; Benzomorphans; Cats; Dopamine Agents; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine; Enkephalins; Feedback, Physiological; Foot; Levodopa; Locomotion; Mechanoreceptors; Monoamine Oxidase Inhibitors; Muscle, Skeletal; Neural Inhibition; Nialamide; Nociceptors; Physical Stimulation; Reflex; Spinal Cord; Tibial Nerve | 2001 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |
Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum.
Topics: Amino Acid Transport System X-AG; Animals; Carrier Proteins; Denervation; Dopamine; Dopamine Agents; Enkephalins; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Excitatory Amino Acid Transporter 3; Female; Fluorescent Antibody Technique; Glutamate Plasma Membrane Transport Proteins; Levodopa; Protein Precursors; Radiography; Rats; RNA, Messenger; Substantia Nigra; Symporters | 2001 |
cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum.
Topics: Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Denervation; DNA; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Enkephalins; Female; Gene Expression; Levodopa; Oligonucleotides, Antisense; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription Factor AP-1 | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dyskinesia, Drug-Induced; Enkephalins; Humans; In Situ Hybridization; Levodopa; Parkinson Disease; Protein Precursors; Putamen; RNA, Messenger; Statistics as Topic | 2002 |
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Neuroprotective Agents; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Triazoles | 2002 |
Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Protein Precursors; RNA, Messenger; Saimiri; Substantia Nigra; Time Factors | 2002 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles | 2002 |
Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Cocaine; Denervation; Dopamine; Dopamine Uptake Inhibitors; Enkephalins; Enzyme Inhibitors; Female; Hydroxydopamines; Immunohistochemistry; In Situ Hybridization; Levodopa; Neostriatum; Neural Pathways; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympathectomy, Chemical | 2003 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Tachykinins; Tyrosine 3-Monooxygenase | 2003 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enkephalins; Entopeduncular Nucleus; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; DNA-Binding Proteins; Enkephalins; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Transcription Factors | 2003 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission | 2004 |
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
Topics: Analysis of Variance; Animals; Autoradiography; Cell Count; Corpus Striatum; DNA-Binding Proteins; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dynorphins; Early Growth Response Protein 1; Enkephalins; Gene Expression Regulation; Immediate-Early Proteins; In Situ Hybridization; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Transcriptional Activation | 2005 |
Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Antagonists; Dynorphins; Enkephalins; Excitatory Amino Acid Transporter 2; Gene Expression Regulation; Levodopa; Male; Neurons; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, Steroid; RNA, Messenger; Transcription Factors; Tyrosine 3-Monooxygenase | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2006 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Agents; Drug Resistance; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neural Pathways; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D3; Receptors, Steroid; Transcription Factors | 2006 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus | 2007 |
Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Down-Regulation; Drug Administration Schedule; Enkephalins; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Up-Regulation; Vesicular Inhibitory Amino Acid Transport Proteins | 2007 |
Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias.
Topics: Animals; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Neurons; Oligonucleotides, Antisense; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2006 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2007 |
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.
Topics: Animals; Benzazepines; Cell Count; Denervation; Dopamine Agents; Dopamine Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Enzyme Activation; Female; Fluorescent Antibody Technique; Immunohistochemistry; In Situ Hybridization; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neostriatum; Neurons, Efferent; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2007 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time | 2007 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time | 2008 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric | 2009 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Isradipine; Levodopa; Male; Motor Activity; Nimodipine; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Sympatholytics | 2009 |
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Female; Fetal Tissue Transplantation; Gene Expression Regulation; Graft Survival; Levodopa; Mesencephalon; Microdialysis; Neurons; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2008 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Electron Transport Complex IV; Enkephalins; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2009 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Levodopa; Mice; Neostriatum; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.
Topics: Animals; Dynorphins; Dyskinesias; Enkephalins; Female; Immunohistochemistry; Levodopa; Male; Mass Spectrometry; Mice; Mice, Knockout; Parkinson Disease; Protein Precursors; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Putamen; Tachykinins | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation | 2014 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger | 2015 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase | 2016 |
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Oxidopamine; Protein Precursors; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P | 2017 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Tyrosine 3-Monooxygenase | 2020 |
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar | 2020 |